[144] Ocular Therapeutix, Inc. SEC Filing

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 1,066 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $13,245.37. The filing shows these shares represent part of the issuer's outstanding common shares of 173,995,221 and identifies the approximate sale date as 09/02/2025 on NASDAQ. The shares were acquired on 08/29/2025 as restricted stock vesting under a registered plan; payment and transfer were recorded that same date. The filer reports no securities sold in the past three months and includes the standard representation regarding absence of undisclosed material adverse information.

Positive

• Clear compliance with Rule 144 reporting requirements via timely Form 144 filing
• Shares acquired by vesting under a registered plan, indicating compensation-related origin rather than external purchase

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale of vested restricted shares, modest in value relative to a public float.

The Form 144 documents a proposed sale of 1,066 vested restricted shares through Morgan Stanley with an indicated market value of $13,245.37 and an intended sale date of 09/02/2025. Acquisition occurred by vesting on 08/29/2025 under a registered plan and no prior sales in the last three months are reported. This is a standard compliance notice required for certain insider sales and does not, by itself, disclose material operational or financial changes at the issuer.

Corporate Governance Expert

TL;DR: Filing reflects routine insider disposition following vesting; compliance with Rule 144 procedures is evident.

The disclosure specifies the relationship to the issuer implicitly via a registered-plan vesting and the use of a broker, which aligns with customary post-vesting sales. The signature block affirms the filer’s statement about lack of undisclosed material adverse information. No indications of aggregated prior sales or trading-plan references are provided in the document.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1066	13245.37	173995221	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted stock vesting under a registered plan	Issuer			1066	08/29/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the OCUL Form 144 report?

The filing reports a proposed sale of 1,066 common shares with aggregate market value $13,245.37 through Morgan Stanley, with an approximate sale date of 09/02/2025.

When and how were the shares acquired according to the filing?

The shares were acquired on 08/29/2025 via restricted stock vesting under a registered plan, with the same date recorded for payment.

Does the filing show prior sales in the past three months for the seller?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker will handle the sale listed in the Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza 8th Floor, New York, NY 10004.

On which exchange is the sale expected to occur?

The filing indicates the sale is expected to occur on NASDAQ.